Depression is a typical neuropsychiatric disorder and has led to great economic and social burden worldwide. During the past few decades, though great efforts have been made on parsing out this mental disease, the potential association of olfactory dysfunctions with depression still remains much to be characterized. Here in this short review, we concisely summarized the evidence of how olfactory dysfunctions acting as a negative marker potentially sign the depression. The olfactory-bulbecomized (OB) rat model highlights the potentially crucial role of olfaction in the pathophysiology of depression. Multiple clinical studies have showed that patients with dysfunctions in olfactory system exhibit a higher probability of depression. Moreover, nowadays the olfaction is considered as a useful approach in the therapy of depression, and olfactory stimulation can potentially ameliorate depressive symptoms. Olfactory dysfunctions, at least in part, are resulted from the decreased olfactory input which can influence neurotransmitter release and potentially changes functioning in limbic and reward related brain areas. The decrease or totally loss of olfactory input may lead to the imbalance of neuronal emotion processing and thereby results in the depressive symptoms in people.
Depression is a typical neuropsychiatric disorder characterized by anhedonia [1,2] which is considered to be the fourth leading cause of disability and will become the second by 2020 [3,4]. Depression has produced great burden to both the economy and society worldwide. During the past few years, though great efforts have been made on parsing out this neurological disorder [4-12], which are accompanied with a plethora of animal models of depression including the olfactory-bulbecomized rat model emerged aiming to unveil the underlying mechanism [4,5,13-15], the association of olfactory dysfunctions with depression still remains much to be characterized. Among these models, the olfactory-bulbecomized (OB) rat model highlights the potentially crucial role of olfaction in the pathophysiology of depression. In the current short review, for concise we only briefly summarized the evidence of how olfactory dysfunction acting as a negative marker potentially signs the depression.
Historic study has suggested that the OB rat is not only a means for testing putative antidepressants but also is a model of depression [14,16]. A growing body of evidence reveals the negative correlation between the olfactory function and depressive symptoms [17-23]. Olfactory dysfunction not only decreases the quality of life but also weakens function and activities of daily living. Clinical studies have showed that patients with dysfunctions in olfactory system exhibited a higher probability of depressive-like phenotypes [24-26], further suggesting olfaction as a negative marker for depression.
This fact is further supported by a recent study indicating that poor odor identification is closely associated with increased depressive symptoms in older male adults [27]. More interestingly, nowadays olfactory dysfunction has been used as a screen measure to discriminate major depression from other neurological disorders such as Alzheimer's disease [28,29], and also the olfactory bulb volume is used to predict the therapeutic outcome of major depression disorder, at least in women patients [30]. In addition, the olfaction is also considered as a useful approach in the therapy of depression, and olfactory stimulation can potentially ameliorate depressive symptoms [18]. The clinical evidence confirmed that performing olfactory training using the Sniffin' Sticks test led to improved olfactory function in patients with olfactory loss [31], which in further could weaken the severity of depressive symptoms in older patients [32]. It was documented that deep brain stimulation or non-invasive brain stimulation targeting the olfactory system produced "immediate relief" on major depression patients [33,34], which has provided new therapeutic opportunities for treatment on patients with depression. Taken together, olfactory dysfunction is a potentially negative marker for depression, and focusing on the improvement of olfactory function in patients with depression could be worthy of considering as a useful measure in ameliorating the depressive symptoms.
The olfactory bulbectomy could result in remarkable modifications in various brain areas, which may be, at least in part, due to the abnormal connections between the olfactory bulb and other brain regions, mainly the olfactory-limbic circuitry [14]. Olfactory dysfunctions such as the decreased volume or destroy of the olfactory bulb may decrease the olfactory input to the limbic system [30]. Some brain areas involved in emotion processing such as amygdaloid nuclei, anterior cingulate cortex, insular regions and orbitofrontal cortex all received strong projections from the olfactory bulb [35]. The decreased olfactory input could influence neurotransmitter release and potentially changed functioning in limbic and reward related brain areas [18]. A decrease or totally loss of olfactory input would also possibly result in the imbalance of neuronal emotion processing and thereby leads to the depressive symptoms in people.
Olfactory dysfunctions in depression patients could happen at both the peripheral and central processing levels. Basically, the peripheral olfactory processing involves the acuity, detection, and sensitivity of olfaction, all of which is evaluated using measures of the olfactory threshold [23,36,37]. Dysfunctions in the peripheral processing are reflected by the weakened processing ability at the level of the nasal epithelium. The central olfactory processing is generally reflected by the identification and discrimination of an odor [23,36-38]. Olfactory processing at these two different levels opens the question that what is the weight of abnormality in peripheral and central olfactory processing, respectively, in the pathogenesis of depression. It is worthy clarifying the potentially different roles of the peripheral and central olfactory system abnormalities in the depressive symptoms in the future studies.